North America's strong demand offset the decline in China and Japan, Toyota's sales in the US reached a new historical high in October.
Toyota Motor Corporation (TM.US) saw an increase in sales in October, with strong demand in the US market effectively offsetting declines in the Chinese and Japanese markets.
Toyota Motor Corp.'s Sponsored ADR (TM.US) saw an increase in sales in October, as strong demand in the U.S. market effectively offset declines in the Chinese and Japanese markets. Despite facing tariff pressures, the continued strong sales of models such as the RAV4 compact crossover SUV demonstrate the company's resilience in operations.
The data released by the Japanese automaker, the largest in Japan, on November 1st, shows that the group's global sales, including subsidiaries such as Daihatsu Motor Co. and Hino Motors Ltd., increased by 3% year-on-year, reaching 1 million units, marking a new monthly record in October. Toyota and Lexus brands saw a 12% increase in sales in the U.S., but a 6.6% decrease in China and a 4.2% drop in the Japanese domestic market.
The data indicates that despite facing tariffs imposed by U.S. President Trump on imported cars and parts, Toyota is increasingly relying on the North American market. At the same time, Prime Minister Shinzo Abe's recent comments on Taiwan have severely strained relations between China and Japan, highlighting the potential impact of political tensions on Toyota's global sales strategy.
Earlier this month, Toyota raised its full-year operating profit outlook despite estimating a loss of 1.4 trillion yen in profit due to the 15% tariff policy - this comes after lowering expectations in August. The automaker currently expects its fiscal year operating profit to reach 3.4 trillion yen by the end of March next year.
It is worth noting that Toyota's global sales of pure electric vehicles surged by 74% year-on-year, reaching 18,322 units.
Related Articles

Beijing Strong Biotechnologies, Inc. (300406.SZ) obtained a medical device registration certificate.

Baozun, Inc. Sponsored ADR Class A (09991, BZUN.US) significantly improved its third-quarter profit indicators, with visibility of growth under the transformation dividend soaring.

Maider Medical Industry Equipment Co. Ltd. (688310.SH) controlling shareholder proposed to repurchase company shares worth 20 to 40 million yuan.
Beijing Strong Biotechnologies, Inc. (300406.SZ) obtained a medical device registration certificate.

Baozun, Inc. Sponsored ADR Class A (09991, BZUN.US) significantly improved its third-quarter profit indicators, with visibility of growth under the transformation dividend soaring.

Maider Medical Industry Equipment Co. Ltd. (688310.SH) controlling shareholder proposed to repurchase company shares worth 20 to 40 million yuan.

RECOMMEND

Hong Kong Stock Buyback Wave Persists, 247 Listed Companies Repurchase Over HKD 150 Billion This Year
27/11/2025

Mingyu Pharmaceutical Files With HKEX: Ongoing Net Losses Since Inception, No Revenue From Commercial Product Sales
27/11/2025

“Affordability Crisis”! Consumer Confidence Falls To Second Lowest Since The Pandemic, U.S. Retail Slumps
27/11/2025


